TCGA-A2-A0YT-01A-11R-A109-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 24
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.550
- PROTEIN_SECRETION+0.490
- G2M_CHECKPOINT+0.470
- MTORC1_SIGNALING+0.400
- MITOTIC_SPINDLE+0.380
- OXIDATIVE_PHOSPHORYLATION+0.350
- MYC_TARGETS_V1+0.320
- UNFOLDED_PROTEIN_RESPONSE+0.320
- ADIPOGENESIS+0.300
- MYC_TARGETS_V2+0.300
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.440
- WNT_BETA_CATENIN_SIGNALING-0.360
- ANGIOGENESIS-0.340
- NOTCH_SIGNALING-0.340
- APICAL_SURFACE-0.300
- COAGULATION-0.270
- KRAS_SIGNALING_UP-0.270
- KRAS_SIGNALING_DN-0.260
- TNFA_SIGNALING_VIA_NFKB-0.260
- ALLOGRAFT_REJECTION-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R408 | — | — | 0.900 |
| 2 | MNG241 | — | — | 0.884 |
| 3 | TCGA-A8-A09N-01A-11R-A00Z-07 | — | B | 0.883 |
| 4 | SRR8942934 | — | — | 0.878 |
| 5 | TCGA-HQ-A5ND-01A-11R-A26T-07 | — | — | 0.875 |
| 6 | TCGA-A8-A092-01A-11R-A00Z-07 | — | B | 0.863 |
| 7 | TCGA-A8-A06O-01A-11R-A00Z-07 | — | B | 0.862 |
| 8 | SRR8942956 | — | — | 0.862 |
| 9 | R135 | — | — | 0.854 |
| 10 | TCGA-4Z-AA80-01A-11R-A39I-07 | — | — | 0.853 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.490 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.470 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.380 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.320 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.290 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.270 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.260 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.250 | Inavolisib | — uncovered |
| PEROXISOME | 0.240 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.170 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.150 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.140 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |